Screener / SEC EDGAR /CIK 0001001316 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

TG Therapeutics, Inc. TGTX

Compare with peers Embed
The 10-K against last year's

242 changes: 63 added, 24 removed, 148 reworded, 7 quiet changes

10-K Feb 27, 2026 vs Mar 3, 2025

10-K 0001437749-26-006133 (Feb 27, 2026) vs 10-K 0001437749-25-005908 (Mar 3, 2025) Not compared: Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

410 paragraphs · 20 new · 109 reworded · 12 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 218 · 49% changed Every version of it
the Drug Supply Chain Security Act (DSCSA), which imposes obligations on entities in the commercial product supply chain, including manufacturers, to identify and track prescription drugs as they are distributed in the U.S.; and state law equivalents of some of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state transparency laws, state laws limiting interactions between pharmaceutical manufacturers and members of the healthcare industry, marketing restrictions and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.
Paragraph 221 · 48% changed Every version of it
We are also exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants, vendors, distributors and consultants agents may engage in fraudulent conduct or other illegal activity. Misconduct While we have policies and procedures in place prohibiting such activity, misconduct by these parties could include intentional failures to comply with include, among other infractions or violations, intentional, reckless and/or negligent conduct or unauthorized activity that violates FDA regulations, provide or foreign regulatory authority requirements, including those laws that require the reporting of true, complete and accurate information to the FDA, comply with FDA or foreign regulatory authorities, manufacturing standards we have established, comply with standards, federal and state healthcare fraud and abuse laws and regulations, report laws that require the true, complete and accurate reporting of financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive other commercial or regulatory laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of ethics applicable to all of our employees and have implemented a compliance program, but it requirements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply be in compliance with these such laws or regulations. In addition, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, regardless of the outcome, our reputation and our business may suffer. If we are not successful in defending ourselves or asserting our rights, those actions could lead to imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business.
Paragraph 201 · 45% changed Every version of it
Furthermore, legislative and regulatory proposals have been made to expand post-approval requirements, make changes the Orphan Drug Act and related guidance, reform the 340B Drug Pricing Program, and restrict sales and promotional activities for drugs. With respect to the 340B Drug Pricing Program, recent legislative proposals, as well as judicial challenges to DHHS’s policies, present both opportunities and challenges for drug manufacturers participating in the program. Further, we We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. Recent policy changes affecting the FDA have resulted in significant changes to research, testing, regulatory approval or clearance, manufacturing and marketing of FDA-regulated products. The FDA has also adopted certain programs, including the PreCheck Program and Commissioner’s National Priority Review Voucher Program, designed to increase domestic production of FDA-regulated products and increased enforcement activities by issuing larger numbers of warning letters to pharmaceutical companies related to violation of regulator standards governing direct-to-consumer advertising. In addition, increased scrutiny by Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. It is not possible at this time Changes to determine whether healthcare regulation and policies, agency priorities, enforcement initiatives and focus, and coverage and reimbursement for healthcare products and services may be sudden and unexpected, and we may experience increased costs to monitor for such changes in the administration may change the regulatory focus and/or implementation of and respond to any regulations, policies or reforms. new requirements affection our business and operations.
Paragraph 200 · 43% changed Every version of it
Furthermore, legislative and regulatory proposals have been made to expand post-approval requirements, make changes the Orphan Drug Act and related guidance, reform the 340B Drug Pricing Program, and restrict sales and promotional activities for drugs. With respect to the 340B Drug Pricing Program, drug discount program, recent legislative proposals, as well as judicial challenges to DHHS’s policies, policies of the Department of Health and Human Services (HHS), present both opportunities and challenges for drug manufacturers participating in the program. Further, we cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. It is not possible at this time to determine whether changes in the administration may change the regulatory focus and/or implementation of any regulations, policies or reforms.
Paragraph 194 · 43% changed Every version of it
We are uncertain of the impact or outcome of potential executive orders, rescission of rules and policy statements, or new legislation to be enacted, especially with regards to the healthcare regulatory and policy landscape, or the impact they may have on our business. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs, or any significant taxes or fees imposed as part of any broader deficit reduction effort could have an adverse impact on our anticipated product revenues. There have been several recent U.S. Congressional inquiries and proposed and enacted legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs and reform government health care program reimbursement methodologies for prescription drugs. In September 2024, CMS issued a final rule titled “Medicaid Program; Misclassification of Drugs, Program Integrity Updates Under the Medicaid Drug Rebate Program” which may impact our reimbursement and rebate strategy. We expect that health care reform measures that The ACA expanded the 340B drug discount program to additional facilities for outpatient drugs. These facilities may be adopted in purchase drugs at the future, may result in increased manufactured financial liability discounted price provided to Medicaid and additional dispense drugs to people with commercial insurance coverage. This program has greatly expanded over time with qualifying facilities establishing relationships with contract pharmacies, which has continued to exert downward pressure on price and profitability of outpatient medicines. Any changes to Medicaid required rebates could also affect our 340B pricing. Other aspects of the price that we may receive for any 340B program are subject to ongoing litigation, the resolution of our product candidates, if approved. Any reduction in reimbursement from Medicare or other government health care programs may result in a similar reduction in payments from private payors. which could impact the scope of the 340B program.
Paragraph 195 · 35% changed Every version of it
The IRA Moreover, the Inflation Reduction Act (IRA) included, among other provisions, several measures intended to lower the cost of prescription drugs and related healthcare reforms. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, Medicare, imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount program with a new discounting program beginning in 2025. We cannot be sure whether additional or related legislation or rulemaking will be issued or enacted, or what impact, if any, such changes will have on the profitability of program. If any of our approved products are subject to price negotiations, it could, among other things, lead to lower revenues prior to the expiry of intellectual property protections. The Medicare drug candidates, if approved for commercial use, in the future. price negotiation program is currently subject to legal challenges and therefore, its outcome remains uncertain.
Paragraph 205 · 34% changed Every version of it
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding Significant workforce reductions and reorganizations at several U.S. health agencies, including the FDA, the HHS, the Centers for Disease Control and Prevention and the National Institutes of Health, have impacted, and may continue to impact, the SEC FDA’s ability to review and other government agencies on which our operations may rely, including those that fund research approve new medicines and development activities is subject to the political process, which is inherently fluid and unpredictable. conduct necessary inspections.
Paragraph 76 · 32% changed Every version of it
expand on our commercialization infrastructure to commercialize BRIUMVI, and/or entering into collaborations with third parties; obtain, develop, maintain, protect, and defend our intellectual property portfolio; and achieve market acceptance of BRIUMVI and any other products for which we may receive regulatory approval in the medical community and with third-party payors.

MD&A

99 paragraphs · 43 new · 38 reworded · 12 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 33 · 48% changed
Our other selling, general and administrative expenses consist primarily of expenses related to the commercialization of our approved products, including salaries products and related the expenses for our commercialization team required to maintain and support a growing commercial development activities. Other selling, general and administrative organization. These expenses consist of executive, finance and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities and facilities-related expenses. include:
Paragraph 74 · 44% changed
On September 2, 2022, August 8, 2025, we filed an automatic “shelf registration” statement on Form S-3 (the 2022 2025 WKSI Shelf) as a “well-known seasoned issuer” WKSI as defined in Rule 405 under the Securities Act, which registered an unlimited and indeterminate amount Act of debt or equity securities for future issuance and sale. 1933, as amended. The 2022 2025 WKSI Shelf was declared effective in September 2022. In connection with upon filing and registers an unlimited amount of debt securities, equity securities, or other securities that we may issue and sell from time to time. The at-the-market program established under our prior shelf registration statement on Form S-3 pursuant to the 2022 WKSI Shelf, we entered into an At-the-Market Issuance Sales Agreement (the 2022 ATM) Agreement, dated September 2, 2022, with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (each a 2022 Agent has expired. We may offer and collectively, sell securities registered under the 2022 Agents), relating 2025 WKSI Shelf in one or more offerings, from time to time, depending on market conditions and our capital needs. We may also file additional registration statements in the sale of shares future to maintain financing flexibility in support of our common stock. Under the 2022 ATM, we will pay the 2022 Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. The 2022 ATM is our only active ATM program. operations.
Paragraph 41 · 43% changed
Product Revenue, net. Product revenue, net was approximately $606.9 million for the year ended December 31, 2025 compared to $313.7 million for the year ended December 31, 2024. Product revenue, net for both the year ended December 31, 2025 and 2024 compared to $92.0 consisted of net product sales of BRIUMVI in the United States of $594.1 million and $310.0 million, respectively. Also included in product revenue, net for the year ended December 31, 2023. 2025 and 2024 are sales of BRIUMVI to our ex-U.S. licensing partner, Neuraxpharm, of $12.8 million and $3.7 million, respectively. The increase in product revenue, net is driven by an increase in product shipments for BRIUMVI as a result of greater market penetration. BRIUMVI, was commercially launched penetration of BRIUMVI in the U.S. in January 2023, following FDA approval. United States and from commercial product sales supplied to Neuraxpharm under the Commercialization Agreement.
Paragraph 50 · 39% changed
Income Taxes. Tax Benefit (Expense). Income tax increased by $1.8 million to $2.2 benefit totaled $339.8 million for the year ended December 31, 2024, 2025, as compared to $0.4 for income tax expense of $2.2 million during the year comparable period ended December 31, 2023. 2024. The increase in income tax benefit is due to state primarily driven by the release of our deferred tax liabilities incurred asset valuation allowance during the year ended December 31, 2024. 2025.
Paragraph 48 · 32% changed
Interest Expense. Interest expense for the year ended December 31, 2024 2025 was $24.0 $26.7 million compared to $12.6 $24.0 million for the comparable period ended December 31, 2023. 2024. The $11.4 $2.7 million increase is mainly due was primarily attributable to $4.6 million of debt extinguishments costs incurred pertaining to the First Amendment with Hercules as well as increased higher interest expense pertaining to incurred under the Initial Term Loan with Blue Owl during the same period year ended December 31, 2025, as compared to interest expense incurred under the prior smaller loan agreement with Hercules, which was outstanding for a portion of the year ended December 31, 2024 (see Note 7 – Loan Payable for more information).
Paragraph 43 · 31% changed
Cost of Revenue. Cost of revenue for the year ended December 31, 2024 2025 was $38.5 $100.7 million compared to approximately $14.1 $38.5 million for the year ended December 31, 2023. 2024. Cost of revenue for both the years ended December 31, 2024 2025 and December 31, 2023 2024 primarily consists primarily of third-party manufacturing, distribution, overhead costs and royalties owed to our licensing partner for BRIUMVI sales. sales, third-party manufacturing, distribution and overhead costs. A portion of the manufacturing costs of producing BRIUMVI sold to date through the middle of the quarter ended March 31, 2025 was expensed as research and development prior to the FDA approval of BRIUMVI and therefore it is not reflected in the cost of revenue. We expect depleted these inventories during the cost of revenue for BRIUMVI to increase in relation to product revenues as we deplete these inventories. We expect to use the remaining pre-commercialization inventory for product sales through the first quarter of 2025, after which our product gross margin is anticipated to decrease modestly. The cost ended March 31, 2025. Cost of revenue for the years quarter ended December 31, 2024 and December 31, 2023 2025 also includes $2.4 a $6.2 million and $1.5 million, respectively, of costs related to delivering regulatory support and development services to Neuraxpharm in accordance with the Commercialization Agreement. inventory reserve.
Paragraph 69 · 29% changed
Cash Net cash used in operating activities for the year ended December 31, 2024 2025 was $40.5 $24.8 million as compared to $31.4 cash used in operating activities of $40.5 million for the year ended December 31, 2023. The increase in net cash used in operating activities was due to higher operating expenditures and an increase in cash used for inventory purchases during the 2024, representing a $15.7 million improvement year ended December 31, 2024. over year.
Paragraph 75 · 29% changed
On August 2, 2024 (the New Closing Date), the Company we entered into a term loan facility of $250 million (the Initial Term Loan) with Blue Owl Capital Corporation, as administrative agent (the Administrative Agent), HealthCare Royalty and Blue Owl Capital under the Financing Agreement (as defined below). The Company repaid below) to repay all outstanding principal and accrued interest and fees under the First Amendment our prior loan agreement with Hercules (such repayment, the Refinancing), which Refinancing was funded with the proceeds of the Initial Term Loan. The existing Amended Loan Agreement with Hercules was effectively terminated, and all guarantees and liens granted thereunder were released upon the consummation of the Refinancing. Hercules.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors328 words changed in this paragraph; it is 40% similar to last year's version.
We are also exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants, vendors, distributors and consultants agents may engage in fraudulent conduct or other illegal activity. Misconduct While we have policies and procedures in place prohibiting such activity, misconduct by these parties could include intentional failures to comply with include, among other infractions or violations, intentional, reckless and/or negligent conduct or unauthorized activity that violates FDA regulations, provide or foreign regulatory authority requirements, including those laws that require the reporting of true, complete and accurate information to the FDA, comply with FDA or foreign regulatory authorities, manufacturing standards we have established, comply with standards, federal and state healthcare fraud and abuse laws and regulations, report laws that require the true, complete and accurate reporting of financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive other commercial or regulatory laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of ethics applicable to all of our employees and have implemented a compliance program, but it requirements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply be in compliance with these such laws or regulations. In addition, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, regardless of the outcome, our reputation and our business may suffer. If we are not successful in defending ourselves or asserting our rights, those actions could lead to imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business.

Source: Item 1A, 10-K 0001437749-26-006133 vs Item 1A, 10-K 0001437749-25-005908

MD&A182 words changed in this paragraph; it is 45% similar to last year's version.
Cost of Product Revenue. Cost of revenue for the year ended December 31, 2023 increased 2024 was $38.5 million compared to the comparable period ended December 31, 2022 due to increased product sales resulting from the commercial launch of BRIUMVI in the U.S. market which began in January 2023 following FDA approval. During approximately $14.1 million for the year ended December 31, 2023 the cost 2023. Cost of revenue consisted for both the years ended December 31, 2024 and December 31, 2023 consists primarily of third-party manufacturing, distribution, overhead costs and royalties on net sales of BRIUMVI owed to our licensing partner. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, a partner for BRIUMVI sales. A portion of the manufacturing costs of BRIUMVI units recognized as revenue during sold through the year middle of the quarter ended December March 31, 2023 were 2025 was expensed as research and development expenses prior to receipt the FDA approval of FDA approval, BRIUMVI and therefore are it is not reflected in the cost of revenue. We expect depleted these inventories during the quarter ended March 31, 2025. The cost of revenue for BRIUMVI the years ended December 31, 2024 and December 31, 2023 includes $2.4 million and $1.5 million, respectively, of costs related to increase delivering regulatory support and development services to Neuraxpharm in relation to product revenues as we deplete these inventories and we expect to use accordance with the remaining pre-commercialization inventory for product sales through the first quarter of 2025. Commercialization Agreement.

Source: Item 7, 10-K 0001437749-26-006133 vs Item 7, 10-K 0001437749-25-005908

Legal Proceedings39 words changed in this paragraph; it is 84% similar to last year's version.
We contract The Company contracts with various third parties to conduct certain activities including clinical operations and contract manufacturing, and for the clinical and commercial supply of BRIUMVI. Certain contracts contain non-cancellable non-cancelable features or require us the Company to make binding forecasts for future purchases. As of December 31, 2024 2025, the Company had aggregate non-cancelable purchase commitments of $214.7 $327.9 million, of which $64.2 $102.3 million, $74.4 million $109.1 million, and $76.1 $116.5 million are expected to be incurred in the years 2025, 2026 2026, 2027 and 2027, 2028, respectively. These amounts do not represent the Company's entire anticipated purchases in the future purchase requirements, as the amounts of such obligations are will ultimately be dependent on the timing of future orders, orders and the terms of the agreement, existing and future agreements, which we believe at this time cannot be reasonably estimated. estimated at this time.

Source: Item 3, via Note 12 – COMMITMENTS AND CONTINGENCIES, 10-K 0001437749-26-006133 vs Item 3, via Note 12 – COMMITMENTS AND CONTINGENCIES, 10-K 0001437749-25-005908

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TGTX's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Mar 3, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
In addition, recent legislative and regulatory proposals in the United States have included “most favored nation” (“MFN”) or international reference pricing models that would tie reimbursement or net prices for certain drugs to the lowest price available in other countries. Adoption or expansion of MFN or similar reference pricing policies could result in downward pressure on U.S. pricing if BRIUMVI or any of our future products are sold at lower net prices in ex-U.S. markets. Because we have partnered the rights to commercialize BRIUMVI in territories outside of the U.S. and do not control pricing, reimbursement negotiations or commercial strategy in those territories, we may have limited ability to influence ex-U.S. pricing decisions that could be used as reference points under MFN or similar frameworks. As a result, pricing determinations made by our collaboration partner in Europe, including in response to local market access dynamics or governmental requirements, could adversely affect the reimbursement or net price realized for BRIUMVI in the U.S. or other markets, which could have a material adverse effect on our revenues and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We may submit additional information to the FDA which the FDA determines constitutes a major amendment to the application and thereby extends the goal date for determination of approvability of the application;
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We may be unable to successfully develop, obtain regulatory approval for, or commercialize a subcutaneous formulation of our approved intravenous product, which could limit our ability to expand our market opportunity and patient reach.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We are conducting a Phase 3 trial evaluating a subcutaneous (SubQ) formulation of ublituximab, which is approved in its intravenous (IV) form for the treatment of RMS. While IV BRIUMVI has demonstrated clinical benefit and gained commercial traction, development and commercialization of a SubQ version of ublituximab presents unique scientific, formulation, clinical, pharmacologic, manufacturing, regulatory, and operational challenges.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
In order to rely on the benefit and risk profile established for IV BRIUMVI in previously conducted pivotal clinical trials, the SubQ form of ublituximab requires optimization of pharmacokinetics to attain equivalent exposure to ensure that efficacy and safety are maintained at levels comparable to the approved IV formulation. Pharmacokinetic (PK) and pharmacodynamic (PD) effects may be reduced or altered when administered SubQ, which could create significant challenges in the development of a SubQ formulation of ublituximab. There is also a risk that systemic exposure, tissue distribution or tissue reactions differ in ways that lead to unforeseen efficacy issues, such as reduced clinical benefit or safety or tolerability issues, including injection site reactions or immunogenicity. Clinical development of a new formulation often takes place alongside process and formulation development, such that the form of the product evaluated in early-stage testing may not be the final form of the product evaluated in late-stage testing or intended to be commercialized, as is the case for SubQ ublituximab development. Furthermore, while early phase clinical trials can provide a general understanding of the bioavailability and tolerability of a SubQ product, they are limited in patient number and duration of follow-up, with the pivotal regimen determined through PK/PD modeling and projections. Such differences in safety, efficacy or PK/PD may not be observed until later stage clinical studies with the final formulation of SubQ ublituximab.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Furthermore, the development of a SubQ formulation, including SubQ ublituximab, typically requires additional clinical studies, including bridging studies and the use of delivery devices (e.g., auto-injectors or prefilled syringes), which may introduce new technical, supply chain, or regulatory challenges. Regulatory agencies may not consider bioequivalence sufficient for approval or may require additional data to demonstrate comparable effectiveness or safety, especially if the SubQ formulations have analytical differences. While the primary outcome of the pivotal clinical trial is to establish equivalent exposure, differences in other clinical properties including but not limited to PD effect, safety, tolerability, and immunogenicity may occur. In such cases, while the primary outcome of the clinical study may be met, regulatory agencies may still consider such a product not pharmaceutically equivalent.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
SubQ formulation may involve higher concentration of the existing IV product, as in the case of SubQ ublituximab, which presents technical and analytical challenges. Concentrated products will have increased viscosity, which will result in decreased yield in the manufacturing process and may increase the cost of goods compared to that of IV BRIUMVI. The high concentration formulations currently under evaluation may not prove to be as stable as the IV BRIUMVI product. If the SubQ formulation is determined to have a shorter shelf life, we may require more inventory or reassess the commercial feasibility for distribution. and if a shorter shelf life is determined that may require either more inventory or even worse, may not be commercially feasible for distribution. Additionally, new supply chains have been and will continue to need to be developed, which adds complexity and magnifies the concerns around reliance on third parties, including establishing new vendors, their timeliness and quality of performance and potential for future supply constraints, and other limitations. Furthermore, the altered physical properties of the subcutaneous material have resulted in certain analytical differences from IV BRIUMVI that may require the development of new analytical methods for product characterization and release, if the current analytical methods used for IV BRIUMVI prove to be inadequate to characterize SubQ ublituximab. Analytical method development is a complex task that has both technical and regulatory implications, and there can be no assurances given that such development will be successful or be completed in a timely manner.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Even if approved, we cannot guarantee that the SubQ formulation of ublituximab will be successfully commercialized or achieve the same level of adoption as the IV formulation. Development, approval, and commercialization of the SubQ formulation of ublituximab will take considerable time and will be subject to completion with existing therapies and new therapies that may become available in the future. Failure to develop or obtain regulatory approval for a SubQ formulation, or to successfully commercialize it if approved, could materially limit our growth in markets that favor self-administration and reduce our competitive positioning relative to other self-administered therapies.
Read it in 10-K Feb 27, 2026 at sec.gov
Show the other 71
AddedRisk Factors
In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act (ACA) made significant changes to the U.S. healthcare system, which included expanding healthcare coverage through Medicaid and implementation of the individual health insurance mandate; changing coverage and reimbursement of drug products under Medicare, Medicaid and 340B government programs; imposing an annual fee on manufacturers of branded drugs; and expanding government enforcement authority. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. The One Big Beautiful Bill Act (OBBBA) has enacted, among others, changes to eligibility requirements for premium tax credits, which is expected to result in less coverage in the ACA’s health insurance marketplace (Marketplace) over the next few years. The ACA premium tax credits expired at the end of 2025, which resulted in an additional loss of coverage for an estimated 24 million people that were previously enrolled in insurance plans obtained through the Marketplace. In addition, the OBBBA has made other changes to the enrollment and eligibility requirements for Medicaid, which is expected to result in the loss of coverage for certain individuals currently enrolled in Medicaid programs. Further, The Centers for Medicare & Medicaid Services (CMS) recently proposed two mandatory payment model pilots, the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, focused on Part D drugs, and Global Benchmark for Efficient Drug Pricing (GLOBE), focused on Part B drugs, which will require pharmaceutical companies to pay additional rebates on certain medicines, including central nervous system agents for the treatment of multiple sclerosis, whose U.S. net-of-discount prices exceed those in certain other countries.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Further, executive orders were signed to implement Most Favored Nation drug pricing policies designed to align certain prescription drug prices in the U.S. to lower prices available in other countries. Investigations are being conducted to examine price differentials and consider policy approaches for implementation, including through administrative action, and letters have been sent to pharmaceutical companies demanding further reduced prices more in line with Most Favored Nation pricing. If such Most Favored Nation policies are implemented, changes to drug pricing are expected to affect the profitability of pharmaceutical and biotech companies in the U.S. as well as in other countries, as a price referencing policy to the U.S. market could make it commercially unviable to commercialize a drug product in a price constrained market. The details of the proposed policies are unclear and the final terms and impact remain uncertain, and may pose long-term risks to our business and our future commercialization plans of our products and product candidates. In addition, the Fair Prescription Drug Prices for Americans Act was re-introduced in May 2025 and proposes to cap the retail list price of prescription drugs and biological products in the United States at the average retail list price for such product among certain countries. Although it is uncertain if these pricing proposals will take effect, reducing drug prices remains a bipartisan effort and, if made effective, could significantly impact coverage, pricing, and reimbursement for any approved product. These and other similar developments could significantly limit the degree of market acceptance of our products or any of our other product candidates that receive marketing authorization. We expect that healthcare reform measures that may be adopted in the future may result in increased manufactured financial liability and additional downward pressure on the price that we may receive for any of our product candidates, if approved. Any reduction in reimbursement from Medicare or other government health care programs may result in a similar reduction in payments from private payors.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
There is also a great degree of uncertainty regarding how the recent U.S. Supreme Court decisions, including Loper Bright Enterprises v. Raimondo and Corner Post, Inc. v. Board of Governors of the Federal Reserve System, will impact FDA’s enforcement and decision-making authority of regulatory agencies, including those of the FDA. Loper Bright explicitly overturned Chevron deference, which previously gave judicial deference to administrative action by agencies in the executive branch. Further, the Supreme Court’s decision in Corner Post may result in challenges to FDA decisions by new litigants long into the future, resulting in greater uncertainty about our continued operations. In February 2025, an executive order was signed asserting greater authority over all federal agencies, including those established by Congress as independent from direct presidential control. The executive order may lead to continued delays, if not cancellations, of pending and proposed regulations at federal agencies and introduces uncertainty as it subjects all significant regulatory actions by the agencies to the President’s supervision and control. We cannot predict the impact that such executive order, any future executive orders or legislation implementing executive orders may have on our business or our results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
We are currently focusing the majority of our efforts on maintaining approval, improving and commercializing BRIUMVI and developing azer-cel for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
In the United States, the President, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act, made significant changes to the U.S. healthcare system, which included expanding healthcare coverage through Medicaid and implementation of the individual health insurance mandate; changing coverage and reimbursement of drug products under Medicare, Medicaid and 340B government programs; imposing an annual fee on manufacturers of branded drugs; and expanding government enforcement authority. The ACA has been the subject of legislative and litigation challenges. We cannot predict whether the new U.S. administration would impose any further changes to the ACA and what effect, if any, such changes to the ACA would have on our business.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
We believe that climate change has the potential to negatively affect our business, results of operations, financial condition and growth prospects. The adverse impacts of climate change include (i) physical risks such as increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat, (ii) risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and (iii) social and human effects (such as population dislocations and harm to health and well-being).
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
New legal or regulatory requirements may also be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in our manufacturing partners being subject to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, upgrading of facilities to meet new building codes, and the redesign of utility systems, which could increase our third-party manufacturers’ operating costs, including the cost of electricity and energy used to develop our products. Our supply chain as a whole would likely be subject to these same transitional risks and would likely pass along any increased costs to us.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
We identified a material weakness in our internal control over financial reporting related to non-routine share-based payment awards, which has been remediated. If we fail to develop and maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be impaired.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
During the preparation of our unaudited condensed consolidated financial statements for the period ended June 30, 2024, we identified a material weakness in our internal control over financial reporting related to a process-level control over share-based payment awards not being designed effectively. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. To remediate the material weakness, the Company has designed and implemented additional preventative controls around non-routine share-based payment awards to ensure the appropriate recognition and measurement of such awards, and enhanced risk assessment procedures to ensure that all non-routine share-based payment awards are appropriately identified and evaluated.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
Management, including our Chief Executive Officer and Chief Financial Officer, has performed testing to verify the effective design and successful operating effectiveness of the new or enhanced controls, determined that control activities have operated effectively for a sufficient period of time and concluded that the previously disclosed material weakness has been remediated as of December 31, 2024.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedRisk Factors
We are also continuing to generate additional clinical data for BRIUMVI to support and potentially expand commercial adoption, including assessing long-term tolerability in our Open-Label Extension of the Phase 3 ULTIMATE I and II trials trials, Phase 3 trial to evaluate subcutaneous ublituximab, Phase 3b ENHANCE trial, the Phase 4 ENABLE real-world observational study and additional Phase 4 clinical studies necessary to satisfy post-approval commitments for regulatory authorities or those undertaken voluntarily by the Company to evaluate the use of BRIUMVI in alternate settings or with alternate methods of administration. authorities.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Moreover, we expect to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue to commercialize BRIUMVI over and continue to advance our clinical trials to evaluate subcutaneous ublituximab, optimize intravenous BRIUMVI for patients with RMS, and evaluate BRIUMVI in other autoimmune diseases and azer-cel for the foreseeable future. treatment of primary progressive MS.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We currently have one marketed product, BRIUMVI, which received approval from the FDA on in December 28, 2022, for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. adults, as well as approval by several regulatory authorities outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In addition, negative or inaccurate postings or comments on social media or networking websites about the Company us or our brands brands, including as a result of collaborations with third parties, could generate adverse publicity that could damage our reputation or the reputation of our brands. brands or harm our relationships with customers, end-users, business partners, investors, or other key stakeholders.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We have adopted a code of ethics applicable to all of our employees and have implemented a compliance program, but it It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply be in compliance with these such laws or regulations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Following the change Any changes in U.S. administration, there is uncertainty regarding future U.S. regulations or policies and legislative and regulatory changes related to taxation and importation, which including as a result of increased tariffs, could adversely impact the global economy and our operating results.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Given However, due to the long lead times and cost of costs associated with establishing and qualifying additional commercial manufacturing sites sites, we expect that we will to rely on single a limited number of contract manufacturers to produce our commercial products under current Good Manufacturing Practice, or cGMP, regulations for the next several years. foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
The California Privacy Rights Act of 2020 (CPRA) significantly expanded the CCPA to grant additional rights to California residents and established a new California data privacy protection agency is authorized to issue substantive regulations and that could result in increased privacy and information security enforcement.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If we do not accurately evaluate the commercial potential or target markets for a particular BRIUMVI and our other product candidate, candidates, we may relinquish valuable rights to that our product candidate candidates or programs through strategic collaboration, licensing, sale or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. candidates or programs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Furthermore, the United States and its European allies other countries have imposed significant sanctions against Russia and Belarus, including regional embargoes, full blocking sanctions, and other restrictions targeting major from doing business with certain Russian companies and financial institutions.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We have established a contract manufacturing relationship with Samsung Biologics for the our primary clinical and commercial supply of BRIUMVI BRIUMVI, and a secondary contract manufacturing relationship with Samsung Biologics. FUJIFILM Diosynth Biotechnologies.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We Further, we may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. unsuccessful for which it would have been more advantageous to enter into a partnering arrangement.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
If we or others identify unexpected side effects or adverse events caused by BRIUMVI or other products or product candidates within the RMS space following introduction into the market, a number of potentially significant negative consequences could result, including:
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
For the foreseeable future, we will have to fund all our operations and capital expenditures from sales of BRIUMVI, cash on hand and amounts raised in future offerings or financings.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that may have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Our product or product candidates may cause undesirable side effects or adverse events that could delay or prevent their regulatory approval or impact their availability and commercial potential after approval.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
If our contract manufacturers cannot do not successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others and the compliance concerns cannot be resolved, remediated, or otherwise addressed to the FDA’s or others’ satisfaction in a timely manner during the review of any marketing applications that we submit, it may negatively impact our ability to obtain regulatory approval for our drug candidates or obtain approval within projected timelines.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), was approved by the U.S. Food and Drug Administration (FDA) in December 2022 and commercially launched in the United States in January 2023. BRIUMVI is administered as a one-hour, twice per year infusion following the starting dose. Since launch, our commercialization efforts have focused on expanding prescriber awareness, increasing penetration across infusion centers and neurology practices, securing payer coverage, and supporting patient access within a competitive RMS treatment landscape.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We believe BRIUMVI’s clinical profile, including its one-hour infusion time and twice-annual dosing schedule, together with demonstrated efficacy and safety in pivotal trials and accumulating real-world experience, supports its positioning within the anti-CD20 therapeutic class. The anti-CD20 class represents a significant segment of the RMS market, reflecting physician familiarity with the mechanism of action and long-term treatment considerations. Our ability to expand adoption is dependent on continued execution across access and site-of-care pathways; however, uptake may be influenced by factors including established prescribing practices, patient switching dynamics, payer coverage and utilization management requirements, competitive contracting, site-of-care logistics, and evolving treatment guidelines.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In August 2023, we entered into a Commercialization Agreement with Neuraxpharm Pharmaceuticals, S.L. (Neuraxpharm), pursuant to which Neuraxpharm obtained rights to commercialize BRIUMVI outside the United States. Under the agreement, we are eligible to receive milestone payments, royalties and revenue from product supply to Neuraxpharm. The timing and magnitude of ex-U.S. revenues depend on country-specific regulatory approvals, pricing and reimbursement determinations, launch timing, and commercial uptake. We provide development, regulatory, and other support services as required under the agreement to facilitate commercialization activities in applicable territories.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The RMS market is highly competitive and includes numerous approved disease-modifying therapies with varying mechanisms of action, routes of administration, safety profiles, and dosing schedules. Competitive dynamics may be influenced by pricing and contracting strategies, payer utilization management practices, the introduction of new branded products or biosimilars, and broader healthcare system and macroeconomic conditions. Our ability to continue to grow BRIUMVI revenues will depend on sustained physician adoption, patient persistence and adherence, competitive differentiation within the anti-CD20 class, and continued access across commercial and government payers.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Our net product revenue is subject to gross-to-net adjustments, including mandatory government discounts and rebates, contractual rebates and chargebacks, trade discounts and allowances (including cash discounts), product returns, distribution fees, and patient support programs. These adjustments are influenced by payer mix, coverage determinations, contracting dynamics, and patient assistance utilization, and may fluctuate from period to period. As our commercial footprint expands and payer contracting strategies evolve, the magnitude and variability of these adjustments may change.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In addition to the ongoing commercialization of BRIUMVI, we continue to invest in our commercial organization, infrastructure, and internal capabilities to support lifecycle management and potential expansion of the product’s clinical and commercial profile. A key area of focus is the development of a subcutaneous formulation of ublituximab, which is being evaluated as a potential alternative route of administration that may offer increased convenience and flexibility for patients and healthcare providers. We are also exploring the use of BRIUMVI in autoimmune indications outside of MS and are advancing early-stage development activities for azer-cel in autoimmune diseases. These programs reflect our broader strategy to enhance the durability of our portfolio and expand future therapeutic opportunities.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Beyond BRIUMVI, we continue to evaluate potential in-licensing and acquisition opportunities. These opportunities may include earlier-stage programs, complementary products, proprietary technologies, or other therapeutic approaches that could enhance our pipeline and support long-term growth. The scope, timing, and level of any such investments will depend on a range of factors, including scientific and clinical data, manufacturing feasibility, regulatory considerations, commercial readiness, available resources, and overall strategic and financial priorities.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
Although we have recently achieved profitability, we have historically incurred substantial operating losses since our inception and may continue to experience fluctuations in operating results. Despite the commercialization of BRIUMVI and the potential future commercialization of other product candidates, there can be no assurance that we will maintain profitability on an ongoing basis.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
For the twelve months ended December 31, 2025, we generated revenue of $616.3 million. Historically, our operating losses have been driven primarily by expenses related to research and development programs and selling, general and administrative costs associated with our operations and commercialization activities to date. Our operating results and cash flows have fluctuated in the past and may continue to vary significantly from period to period. We will need to generate substantial revenues to sustain profitability and positive cash flow over the long term.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
As of December 31, 2025, our accumulated deficit was approximately $1.1 billion, and we had $199.5 million in cash and cash equivalents, and investment securities. Based on our current operating plan and results, we anticipate that our existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet our liquidity needs for more than twelve months after the date of issuance of this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The actual level of cash required for operations will depend on numerous factors, including, among others, the scope of commercialization activities for BRIUMVI, the timing of collection of receivables from our customers on extended payment terms, the timing and design of clinical trials for our product candidates, and the costs associated with licensing or acquiring new product candidates. We may seek significant additional financing in the future to support strategic initiatives and our ongoing and planned operations.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We expect our expenses to increase as we continue to grow and expand our clinical programs and pursue the potential commercialization of additional product candidates. We anticipate incurring significant research and development expenses related to these activities for the foreseeable future. The actual amount of cash needed to support these strategic initiatives will depend on many factors, including:
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
In February of 2021, we announced that the FDA granted accelerated approval of umbralisib, the Company’s PI3K delta inhibitor, then commercially referred to as UKONIQ, for the treatment of adult patients with relapsed or refractory MZL who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory FL who have received at least three prior lines of systemic therapy. In April of 2022, we announced the voluntary withdrawal of UKONIQ from sale for the approved indications. Our only source of product revenues during the year ended December 31, 2022 was from the sale of UKONIQ. Our only source of product revenues during the years ended December 31, 2023 and 2024, was from the sale of BRIUMVI. Product revenues are recorded net of estimates of variable consideration. For further discussion of our revenue recognition policy, see “Critical Accounting Policies and Significant Judgements and Estimates” below.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Our other research and development expenses consist primarily of expenses relating to the design, development, manufacture, testing and enhancement of our drug candidates and technologies, milestone expenses related to in-licensing of new product candidates, fees paid to consultants and outside service providers for clinical and laboratory development, personnel expenses and other facilities-related expenses. We expense our research and development costs as they are incurred. Research and development expenses for the years ended December 31, 2024, 2023 and 2022 were approximately $83.1 million, $63.2 million and $112.1 million respectively, excluding noncash compensation expenses related to research and development.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
(in thousands) 2024 2023 Product revenue, net $ 313,728 $ 92,005 License, milestone, royalty and other revenue 15,276 141,657 Total Revenue $ 329,004 $ 233,662 Costs and expenses: Cost of revenue 38,486 14,131 Research and development: Noncash compensation 11,160 13,010 Other research and development 83,131 63,182 Total research and development 94,291 76,192 Selling, General and administrative: Noncash compensation 31,381 24,923 Other selling, general and administrative 122,917 97,783 Total selling, general and administrative 154,298 122,706 Total costs and expenses 287,075 213,029 Interest expense 24,028 12,615 Other income (7,693) (5,044) Total other expense, net 16,335 7,571 Net income before taxes 25,594 13,062 Income taxes 2,211 390 Net income $ 23,383 $ 12,672
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
(in thousands) 2023 2022 Product revenue, net $ 92,005 $ 2,633 License, milestone and other revenue 141,657 152 Total Revenue $ 233,662 $ 2,785 Costs and expenses: Cost of product revenue 14,131 265 Research and development: Noncash compensation 13,010 13,224 Other research and development 63,182 112,128 Total research and development 76,192 125,352 General and administrative: Noncash compensation 24,923 31,438 Other selling, general and administrative 97,783 64,046 Total general and administrative 122,706 95,484 Total costs and expenses 213,029 221,101 Interest expense 12,615 10,191 Other income (5,044) (4,695) Total other expense, net 7,571 5,496 Net income (loss) before taxes 13,062 (223,812) Income taxes 390 — Net income (loss) $ 12,672 $ (223,812)
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Historically, we have incurred operating losses since our inception; however, during the year ended December 31, 2024, and December 31, 2023 the Company generated net income. During the year ended December 31, 2023, the Company experienced a net profit due to a $140.0 million non-refundable upfront payment recognized as license revenue in the third quarter of 2023 as part of our Commercialization Agreement with Neuraxpharm (see Note 2 for more information). We may incur operating losses in the near term and may never become profitable. As of December 31, 2024, we have an accumulated deficit of $1.5 billion.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
Our major sources of cash have been proceeds from private placements and public offerings of equity securities, from our loan and security agreements, the upfront payment from the Commercialization Agreement (see Note 2 for more information), and from product revenue from drug sales of BRIUMVI. Substantially all our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations, including our commercialization activities. As of December 31, 2024, we generated $313.7 million in product revenue from sales of BRIUMVI. BRIUMVI first became commercially available in the United States in January 2023. Even with the commercialization of BRIUMVI and the possible future commercialization of our other drug candidates, we may not realize continued profitability. Our ability to achieve continued profitability depends on our ability to generate revenue and many other factors, including our ability to successfully commercialize our drug candidates alone or in partnership; successfully complete any post-approval regulatory obligations and our ability to maintain or obtain regulatory approval for our drug candidates. We may incur operating losses even now that we are generating revenues from BRIUMVI.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
As of December 31, 2024, we had $311.0 million in cash and cash equivalents, and short-term investment securities. We anticipate that our cash, cash equivalents, and investment securities as of December 31, 2024, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will provide sufficient liquidity for more than a twelve-month period from the date of filing this Annual Report on Form 10-K. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, our commercialization efforts for BRIUMVI, and the timing, design and conduct of clinical trials for our drug candidates as well as the costs associated with licensing or otherwise acquiring new product candidates. We may be dependent upon significant future financing to provide the cash necessary to execute our ongoing and future operations, including the commercialization of any of our drug candidates.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
During the year ended December 31, 2023, we sold a total of 1,385,700 shares of common stock under the 2022 ATM for aggregate total gross proceeds of approximately $47.1 million at an average selling price of $34.01 per share, resulting in net proceeds of approximately $46.3 million after deducting commissions and other transactions costs.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The 2022 WKSI Shelf is currently our only active shelf registration statement. We may offer any combination of the securities registered under the 2022 WKSI Shelf from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We may need to file additional shelf registration statements in the future to provide us with the flexibility to raise additional capital to finance our operations as needed.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
On March 31, 2023 (the First Amendment Effective Date), the Company entered into a First Amendment to the Amended and Restated Loan and Security Agreement (the First Amendment) with Hercules Capital, Inc. (Hercules). The First Amendment amended the terms of the Amended and Restated Loan and Security Agreement (Amended Loan Agreement) with Hercules that closed on December 30, 2021. The First Amendment amended the terms of the Amended Loan Agreement to, among other things, (i) issue an advance of $25.0 million drawn at the First Amendment Effective Date (the Tranche 3A Advance), (ii) provide for the formal expiration of Tranche 2, (iii) change the draw amounts and dates available under subsequent tranches, including splitting the remaining balance of Tranche 3 into two additional advances in an aggregate principal amount of up to $20.0 million, in increments of $10.0 million (a Tranche 3B Advance and a Tranche 3C Advance), decreasing the amount available under Tranche 4 from $65.0 million to $60.0 million, and adding a Tranche 5 of $25.0 million, subject to the achievement of revenue related performance milestones, (iv) extend the interest only period from February 1, 2025 to August 1, 2025 and (v) modify the cash interest rate to be the greater of either (a) the “prime rate” as reported in The Wall Street Journal plus 1.20%, and (b) 8.95%. In addition to the cash interest rate, the principal balance will accrue paid-in-kind interest at a rate of 2.25%, which amount will be capitalized and added to the outstanding principal balance of the Amended Term Loan and payable at the maturity date of the Amended Loan Agreement, as amended, The Amended Loan Agreement, as amended, contains financial covenants that require the Company to maintain certain levels of unrestricted cash and additional financial covenants related to market capitalization.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
The Amended Loan Agreement, as amended also contains warrant coverage of 2.95% of the total amount funded. A warrant (the Warrant) was issued by the Company to Hercules to purchase 115,042 shares of common stock with an exercise price of $17.95 for the initial amount funded at the Closing Date. The Warrant shall be exercisable for seven years from the date of issuance. Hercules may exercise the Warrant either by (a) cash or check or (b) through a net issuance conversion. Additionally, a warrant was issued by the Company to Hercules to purchase 50,172 shares of common stock with an exercise price of $14.70 for the amount funded pertaining to the Tranche 3A Advance (the First Amendment Warrant). The First Amendment Warrant shall be exercisable for seven years from the date of issuance. Hercules may exercise the First Amendment Warrant either by (a) cash or check or (b) through a net issuance conversion.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedMD&A
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). The amendments in ASU No. 2023-07 apply to public entities, including those with a single reportable segment, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has evaluated the impact ASU No. 2023-07 on its consolidated financial statements. The Company has adopted this standard as of December 31, 2024 and noted there was no material impact on the Company's consolidated financial statements. The adoption did result in enhanced disclosures as included in Note 1 - Organization and Summary of Significant Accounting Policies.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedMD&A
The increase in other research and development expense during the year ended December 31, 2024 was primarily attributable due to an increase in manufacturing expense, including manufacturing and development costs incurred in connection with our subcutaneous ublituximab subcutaneous development work, increased clinical trial related expenses pertaining to our clinical pipeline, and increased personnel and costs associated with the Precision License Agreement incurred during the period. period ended December 31, 2025, as compared to the year ended December 31, 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Based on In accordance with our policy to expense costs associated with the manufacture of our products prior to regulatory approval, a portion of the manufacturing costs of incurred to produce BRIUMVI units recognized as revenue during the years ended before its FDA approval in December 31, 2023 and 2024 2022 were expensed prior to receipt of FDA approval on December 28, 2022, research and therefore are not included in costs of product revenue during those periods.​ development.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, As a result, a portion of the manufacturing costs of BRIUMVI units recognized as revenue during the years ended December 31, 2025, 2024 and 2023 and 2024 were expensed prior to receipt of FDA approval on December 28, 2022, and therefore are not included in costs the cost of product revenue during those periods.​
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Food and Drug Administration (FDA) for BRIUMVI® BRIUMVI (ublituximab-xiiy) for the treatment of to treat adult patients with relapsing forms of multiple sclerosis (RMS), to include including clinically isolated syndrome, relapsing-remitting disease disease, and active secondary progressive disease, in adults, as well as approval by from several regulatory agencies outside of the European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom (UK), respectively. features.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The decrease increase in noncash compensation expense was primarily due to decreased vesting greater recognition of milestone-based grants noncash compensation expense for performance-based awards and the grant-date fair value of equity awards, including the impact of our increased stock price at which equity awards were granted, during the year ended December 31, 2024, 2025, as compared to the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
License, milestone, royalty and other revenue for the year ended December 31, 2023 2025 is predominantly comprised of recognition $3.8 million consideration received for development and regulatory activities performed on behalf of Neuraxpharm in accordance with the one-time $140.0 Commercialization Agreement and $5.6 million non-refundable upfront payment of royalty revenue recognized under the Commercialization Agreement with Neuraxpharm (see Note 2 - Revenue for more information). ​
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
In connection with The at-the-market program established under our prior shelf registration statement on Form S-3 pursuant to the 2022 WKSI Shelf, we entered into an At-the-Market Issuance Sales Agreement (the 2022 ATM) Agreement, dated September 2, 2022, with Cantor Fitzgerald & Co. and B.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The increase Net cash used in net cash provided by financing activities during the year ended December 31, 2024 2025 is mainly due to the proceeds from the new loan with Blue Owl, offset by the payoff repurchase of stock under our prior loan with Hercules. share repurchase program.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
On September 2, 2022, August 8, 2025, we filed an automatic “shelf registration” statement on Form S-3 (the 2022 2025 WKSI Shelf) as a “well-known seasoned issuer” WKSI as defined in Rule 405 under the Securities Act, which registered an unlimited and indeterminate amount Act of debt or equity securities for future issuance and sale. 1933, as amended.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
License, milestone, royalty and other revenue for the year ended December 31, 2024 is predominately comprised of a the recognition of the one-time $12.5 million milestone payment under the Neuraxpharm Commercialization Agreement for the first key market commercial launch of BRIUMVI in the EU, as well as consideration received for development and regulatory activities performed on behalf of Neuraxpharm in accordance with the Commercialization Agreement. EU.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The applicable margin for borrowings of the Initial Term Loan is determined on a quarterly basis by reference to a pricing grid based on the achievement of US Net Sales (as defined in the Financing Agreement) for the most recently completed four consecutive fiscal quarters of the Company and its Subsidiaries (as defined in the Financing Agreement). U.S.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The increase in noncash compensation expense was primarily due to greater recognition of noncash compensation expense for grants to executives performance and market-based equity awards, growth in headcount, and higher grant-date stock prices associated with equity awards granted during the year ended December 31, 2025, as compared to the year ended December 31, 2024.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TGTX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.